Christianna Finn, NP
Adult Health · Long Beach, CANPI 1417661489
Payments from drug & device makers
Across 16 payments — averaging $36.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$268
- Edwards Lifesciences$141
- Lilly USA, LLC$46
- Exact Sciences$36
- Boehringer Ingelheim$34
- Boston Scientific$31
- plus $34 from 2 others
What the payments were for
- Food & beverage$590100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $268 |
| Edwards Lifesciences | 1 | $141 |
| Lilly USA, LLC | 2 | $46 |
| Exact Sciences | 2 | $36 |
| Boehringer Ingelheim | 1 | $34 |
| Boston Scientific | 1 | $31 |
| Amgen | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$590 in reported general payments places this provider in the 60th percentile of 785 adult health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 29 | $384 |
| Ibandronate Sodium | 13 | $304 |
| Rosuvastatin Calcium | 17 | $303 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $300 |
| Alprazolam | 33 | $285 |
| Metformin Hcl | 17 | $240 |
| Amlodipine Besylate | 19 | $168 |
| Zolpidem Tartrate | 13 | $156 |
| Atorvastatin Calcium | 21 | $110 |
| Losartan Potassium | 15 | $89 |
| Hydrocortisone | 12 | $85 |
| Lorazepam | 23 | $78 |
| Tramadol Hcl | 14 | $73 |
| Hydrochlorothiazide | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Other adult health in Long Beach
- Jennifer VicenteLong Beach$6K
- Karolina FaysmanLos Angeles$1.1M
- Siok-Hian Tay-KelleyStanford$611K
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.